Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 DMX-200 in focal segmental glomerulosclerosis on background ARB therapy
2023-504597-37-00Phase 3Authorised
- Sponsor
- Dimerix
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing DMX-200 + ARB with Placebo + ARB (2 arms). Primary endpoints: Percent change in urine protein/creatinine ratio, Mean change in estimated glomerular filtration rate and 3 more. Planned start Jun 2023; status: authorised.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2023-504597-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504597-37-00.